IQX Limited (NSX:IQX) Progress of Clinical Programs
Progress of Clinical ProgramsSydney, April 29, 2021 AEST (ABN Newswire) - iQX Limited (iQX Ltd) (
NSX:IQX) would like to announce that Life Science Biosensor Diagnostics Pty Ltd (LSBD) in which iQX Ltd holds a 19% equity position, has received approval from the Harvard Longwood campus Institutional Review Board (IRB) to commence a clinical validation study to test patient samples from a COVID-19 repository. The study follows a partnership with the Wyss Institute for Biologically Inspired Engineering at Harvard University (Wyss Institute), through Life Science Biosensor Diagnostics Pty Ltd subsidiary, GBS Inc. (
Nasdaq:GBS), a Delaware corporation, to develop a novel diagnostic SARS-CoV-2 test.